PRESS RELEASE

Q2 2021 — Press release

Q2 2021PDF · 20 pages565 KB
FOR IMMEDIATE RELEASE
• Strong sales growth of 27.1% to $23.3 Billion in Second Quarter 2021 with operational growth of 23.0%*
and adjusted operational growth of 23.8%*
• EPS of $2.35 increased 72.8% in Second Quarter 2021 and adjusted EPS of $2.48 increased 48.5%*
• Company increasing 2021 Full-Year guidance for sales and EPS
New Brunswick, N.J. (July 21, 2021) – Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter.
“Our second-quarter results showcase Johnson & Johnson’s diversified portfolio, driven by strong sales and earnings
growth across our Medical Device, Consumer Health and Pharmaceutical businesses,” said Alex Gorsky, Chairman
and Chief Executive Officer. “I’m so proud of our 136,000 colleagues who remain focused on delivering our medicines
and products to patients and consumers around the world, in addition to advancing our pipeline with new product
launches and regulatory submissions. These accomplishments exemplify our commitment to advancing
transformational innovations that improve the health of people and communities everywhere while continuing to deliver
long-term value to all of our stakeholders.”
OVERALL FINANCIAL RESULTS
1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules
2 Excludes the impact of translational currency
3 Excludes the net impact of acquisitions and divestitures and translational currency
4 Excludes intangible amortization expense and special items

-- 1 of 20 --

REGIONAL SALES RESULTS
1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules
2 Excludes the impact of translational currency
3 Excludes the net impact of acquisitions and divestitures and translational currency
Note: values may have been rounded
SEGMENT SALES RESULTS
1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules
2 Excludes the impact of translational currency
3 Excludes the net impact of acquisitions and divestitures and translational currency
Note: values may have been rounded
Second Quarter 2021 SEGMENT COMMENTARY:
Consumer Health
Consumer Health worldwide operational sales, excluding the net impact of acquisitions and divestitures, increased
10.0%* inclusive of the market recovery from COVID-19 impacts, primarily in skin health/beauty. Sales growth was
driven by skin health/beauty products including NEUTROGENA, AVEENO, and OGX; over-the-counter products
including ZYRTEC in upper respiratory products, international analgesics, and digestive health products; and BAND-
AID® Brand Adhesive Bandages in wound care products.
Pharmaceutical
Pharmaceutical worldwide operational sales, excluding the net impact of acquisitions and divestitures, grew 14.1%*
driven by STELARA (ustekinumab), a biologic for the treatment of a number of immune-mediated inflammatory
diseases, DARZALEX (daratumumab), for the treatment of multiple myeloma, TREMFYA (guselkumab), a biologic
for the treatment of adults living with moderate to severe plaque psoriasis, and for adults with active psoriatic arthritis,
ERLEADA (apalutamide), a next-generation androgen receptor inhibitor for the treatment of patients with prostate
cancer, IMBRUVICA (ibrutinib), an oral, once-daily therapy approved for use in treating certain B-cell malignancies,

-- 2 of 20 --

a type of blood or lymph node cancer, and INVEGA SUSTENNA/XEPLION/INVEGA TRINZA/TREVICTA
(paliperidone palmitate), long-acting, injectable atypical antipsychotics for the treatment of schizophrenia in adults.
This growth was partially offset by biosimilar and generic competition, with declines primarily in REMICADE
(infliximab), a biologic approved for the treatment of a number of immune-mediated inflammatory diseases.
Medical Devices
Medical Devices worldwide operational sales, excluding the net impact of acquisitions and divestitures, grew 58.7%*,
primarily driven by the benefit of market recovery from COVID-19 impacts and the associated deferral of medical
procedures in the prior year across all of our businesses including Surgery, Orthopaedics, Vision and Interventional
Solutions.

-- 3 of 20 --

NOTABLE NEW ANNOUCEMENTS IN THE QUARTER:
The information contained in this section should be read in conjunction with Johnson & Johnson’s other disclosures
filed with the Securities and Exchange Commission, including its Current Reports on Form 8-K, Quarterly Reports on
Form 10-Q and Annual Reports on Form 10-K. Copies of these filings are available online at www.sec.gov,
www.jnj.com or on request from Johnson & Johnson. The reader is also encouraged to review all other news releases
available online in the Investors section of the company’s website at news releases.
Regulatory
Decisions
TECNIS SYNERGY and TECNIS SYNERGY TORIC II IOLS a Next Generation Treatment
for Cataract Patients Received Regulatory Approval and Launched in the U.S. and Canada
(press release)
(press release)
RYBREVANT (amivantamab-vmjw) Receives U.S. FDA Approval as the First Targeted
Treatment for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion
Mutations
(press release)
PONVORY (ponesimod) receives European Commission approval for the Treatment of
Adults with Relapsing Forms of Multiple Sclerosis with Active Disease Defined by Clinical or
Imaging Features
(press release)
DARZALEX (daratumumab) Subcutaneous (SC) Formulation Becomes the First Approved
Treatment for Newly Diagnosed Systemic Light Chain Amyloidosis in Europe and Gains an
Additional Approval in Pre-Treated Multiple Myeloma
(press release)
DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) Receives U.S. FDA Approval
for Combination with Pomalidomide and Dexamethasone for Patients with Multiple Myeloma
After First or Subsequent Relapse1
(press release)
Regulatory
Submissions
Janssen granted Breakthrough Therapy Designation from the U.S. FDA for Teclistamab for
the Treatment of Relapsed or Refractory Multiple Myeloma (press release)
Janssen Submits Marketing Authorisation Application to the European Medicines Agency for
BCMA CAR-T Therapy Ciltacabtagene Autoleucel (cilta-cel) for the Treatment of Relapsed
and/or Refractory Multiple Myeloma
(press release)
Janssen Submits New Drug Application to U.S. FDA for XARELTO (rivaroxaban) to Help
Prevent and Treat Blood Clots in Pediatric Patients (press release)
Other
Johnson & Johnson Joins World Health Organization in Efforts to Prevent Spread of Ebola in
West Africa (press release)
Janssen Discontinues Collaboration and License Agreement with argenx for Cusatuzumab (press release)
ETHICON expands Advanced Bipolar Energy Portfolio with Launch of ENSEAL X1 Curved
Jaw Tissue Sealer (press release)
Johnson & Johnson Announces Positive New Data for the Single-Shot COVID-19 Vaccine on
Activity Against Delta Variant and Long-lasting Durability of Response (press release)
Johnson & Johnson Consumer Inc. Issues Voluntary Recall of Specific NEUTROGENA and
AVEENO Aerosol Sunscreen Products Due to the Presence of Benzene1 (press release)
1Subsequent to the quarter

-- 4 of 20 --

FULL-YEAR 2021 GUIDANCE:
Johnson & Johnson does not provide GAAP financial measures on a forward-looking basis because the company is
unable to predict with reasonable certainty the ultimate outcome of legal proceedings, unusual gains and losses,
acquisition-related expenses and purchase accounting fair value adjustments without unreasonable effort. These
items are uncertain, depend on various factors, and could be material to Johnson & Johnson's results computed in
accordance with GAAP.
($ in Billions, except EPS) April 2021 July 2021 (Base Business) July 2021 (incl. COVID Vx)
Adjusted Operational Sales1,2
Change vs. Prior Year 8.7% - 9.9% 9.5% - 10.5% 12.5% - 13.5%
Operational Sales2
Change vs. Prior Year
$89.3B - $90.3B
8.2% – 9.4%
$90.0B - $90.8B
9.0% – 10.0%
$92.5B - $93.3B
12.0% – 13.0%
Estimated Reported Sales3
Change vs. Prior Year
$90.6B - $91.6B
9.7% – 10.9%
$91.3B - $92.1B
10.5% – 11.5%
$93.8B - $94.6B
13.5% – 14.5%
Adjusted Operational EPS
(Diluted)2,4
Change vs. Prior Year
$9.30 - $9.45
15.8% - 17.7%
$9.50 - $9.60
18.4% - 19.6%
Adjusted EPS (Diluted)3,4
Change vs. Prior Year
$9.42 - $9.57
17.3% - 19.2%
$9.60 - $9.70
19.6% - 20.8%
1 Non-GAAP financial measure; excludes the net impact of acquisitions and divestitures
2 Non-GAAP financial measure; excludes the impact of translational currency
3 Calculated using Euro Average Rate: April 2021 = $1.19 and July 2021 = $1.19 (Illustrative purposes only)
4 Non-GAAP financial measure; excludes intangible amortization expense and special items
Note: % may have been rounded
Other modeling considerations will be provided on the webcast.
WEBCAST INFORMATION:
Johnson & Johnson will conduct a conference call with investors to discuss this earnings release today at 8:30 a.m.,
Eastern Time. A simultaneous webcast of the call for investors and other interested parties may be accessed by
visiting the Johnson & Johnson website. A replay and podcast will be available approximately two hours after the live
webcast in the Investors section of the company's website at events-and-presentations.

-- 5 of 20 --

ABOUT JOHNSON & JOHNSON:
At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward
progress. That’s why for more than 130 years, we have aimed to keep people well at every age and every stage of
life. Today, as the world’s largest and most broadly-based health care company, we are committed to using our reach
and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy
mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity
to profoundly change the trajectory of health for humanity.
NON-GAAP FINANCIAL MEASURES:
*Operational sales growth excluding the impact of translational currency, adjusted operational sales growth excluding
the net impact of acquisitions and divestitures and translational currency, as well as adjusted net earnings, adjusted
diluted earnings per share and adjusted operational diluted earnings per share excluding after-tax intangible
amortization expense and special items, are non-GAAP financial measures and should not be considered
replacements for, and should be read together with, the most comparable GAAP financial measures. Except for
guidance measures, reconciliations of these non-GAAP financial measures to the most directly comparable GAAP
financial measures can be found in the accompanying financial schedules of the earnings release and the Investors
section of the company's website at quarterly-results.
Copies of the financial schedules accompanying this earnings release are available on the company’s website at
quarterly-results. These schedules include supplementary sales data, a condensed consolidated statement of
earnings, reconciliations of non-GAAP financial measures, and sales of key products/franchises. Additional
information on Johnson & Johnson, including adjusted income before tax by segment, a pharmaceutical pipeline of
selected compounds in late stage development and a copy of today’s earnings call presentation can also be found in
the Investors section of the company's website at quarterly-results.
NOTE TO INVESTORS CONCERNING FORWARD-LOOKING STATEMENTS:
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of
1995 regarding, among other things: future operating and financial performance, product development, market
position and business strategy. The reader is cautioned not to rely on these forward-looking statements. These
statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known
or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and
projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: risks related to the impact
of the COVID-19 global pandemic, such as the scope and duration of the outbreak, government actions and restrictive
measures implemented in response, material delays and cancellations of medical procedures, supply chain
disruptions and other impacts to the business, or on the Company’s ability to execute business continuity plans, as a
result of the COVID-19 pandemic, economic factors, such as interest rate and currency exchange rate fluctuations;
competition, including technological advances, new products and patents attained by competitors; challenges inherent

-- 6 of 20 --

in new product research and development, including uncertainty of clinical success and obtaining regulatory
approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of
patent expirations; the ability of the Company to successfully execute strategic plans; the impact of business
combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; product
efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government
action, including related to product liability claims; changes to applicable laws and regulations, including tax laws and
global health care reforms; trends toward health care cost containment; changes in behavior and spending patterns
of purchasers of health care products and services; financial instability of international economies and legal systems
and sovereign risk; increased scrutiny of the health care industry by government agencies. A further list and
descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on
Form 10-K for the fiscal year ended January 3, 2021 including in the sections captioned “Cautionary Note Regarding
Forward-Looking Statements” and “Item 1A. Risk Factors,” in the Company’s most recently filed Quarterly Report on
Form 10-Q and the Company’s subsequent filings with the Securities and Exchange Commission. Copies of these
filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Any forward-looking
statement made in this release speaks only as of the date of this release. Johnson & Johnson does not undertake to
update any forward-looking statement as a result of new information or future events or developments.
Press Contacts: Investor Contacts:
Christina Chan Courtney Dugan Christopher DelOrefice Jennifer McIntyre
(732) 524-6297 (347) 452-1061 (732) 524-2955 (732) 524-3922

-- 7 of 20 --

Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)
Percent Change
2021 	2020 	Total 	Operations 	Currency 	2021 	2020 	Total 	Operations 	Currency
Sales to customers by
segment of business
Consumer Health
U.S. 	1,751	$ 	1,557 	12.4 % 	12.4 	- 	3,362	$ 	3,297 	2.0 % 	2.0 	-
International 	1,984 	1,739 	14.1 	6.3 	7.8 	3,916 	3,624 	8.1 	3.3 	4.8
3,735 	3,296 	13.3 	9.2 	4.1 	7,278 	6,921 	5.2 	2.7 	2.5
Pharmaceutical
U.S. 	6,869 	6,120 	12.2 	12.2 	- 	13,315 	12,181 	9.3 	9.3 	-
International 	5,730 	4,632 	23.7 	15.4 	8.3 	11,483 	9,705 	18.3 	11.4 	6.9
12,599 	10,752 	17.2 	13.6 	3.6 	24,798 	21,886 	13.3 	10.3 	3.0
Medical Devices
U.S. 	3,299 	1,862 	77.2 	77.2 	- 	6,353 	4,760 	33.5 	33.5 	-
International 	3,679 	2,426 	51.6 	41.9 	9.7 	7,204 	5,460 	31.9 	24.5 	7.4
6,978 	4,288 	62.7 	57.2 	5.5 	13,557 	10,220 	32.7 	28.7 	4.0
U.S. 	11,919 	9,539 	24.9 	24.9 	- 	23,030 	20,238 	13.8 	13.8 	-
International 	11,393 	8,797 	29.5 	20.9 	8.6 	22,603 	18,789 	20.3 	13.7 	6.6
Worldwide 	23,312	$ 	18,336 	27.1 % 	23.0 	4.1 	45,633	$ 	39,027 	16.9 % 	13.7 	3.2
Note: Percentages have been calculated using actual, non-rounded figures and,
therefore, may not recalculate precisely.
SECOND QUARTER 	SIX MONTHS
Percent Change

-- 8 of 20 --

Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)
Percent Change
2021 	2020 	Total 	Operations 	Currency 	2021 	2020 	Total 	Operations 	Currency
Sales to customers by
geographic area
U.S. 	11,919	$ 	9,539 	24.9 % 	24.9 	- 	23,030	$ 	20,238 	13.8 % 	13.8 	-
Europe 	5,668 	4,063 	39.5 	28.6 	10.9 	11,082 	8,890 	24.7 	15.6 	9.1
Western Hemisphere excluding U.S. 	1,367 	1,133 	20.6 	12.7 	7.9 	2,791 	2,635 	5.9 	5.4 	0.5
Asia-Pacific, Africa 	4,358 	3,601 	21.0 	14.8 	6.2 	8,730 	7,264 	20.2 	14.2 	6.0
International 	11,393 	8,797 	29.5 	20.9 	8.6 	22,603 	18,789 	20.3 	13.7 	6.6
Worldwide 	23,312	$ 	18,336 	27.1 % 	23.0 	4.1 	45,633	$ 	39,027 	16.9 % 	13.7 	3.2
Note: Percentages have been calculated using actual, non-rounded figures
and, therefore, may not recalculate precisely.
SECOND QUARTER 	SIX MONTHS
Percent Change

-- 9 of 20 --

Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings
(Unaudited; in Millions Except Per Share Figures)
Percent
Percent 	Percent 	Increase
Amount 	to Sales 	Amount 	to Sales 	(Decrease)
Sales to customers 	23,312	$ 	100.0 	18,336	$ 	100.0 	27.1
Cost of products sold 	7,587 	32.5 	6,579 	35.9 	15.3
Gross Profit 	15,725 	67.5 	11,757 	64.1 	33.8
Selling, marketing and administrative expenses 	6,073 	26.1 	4,993 	27.2 	21.6
Research and development expense 	3,394 	14.6 	2,707 	14.8 	25.4
In-process research and development 	0 	0.0 	6 	0.0
Interest (income) expense, net 	28 	0.1 	26 	0.2
Other (income) expense, net 	(488) 	(2.1) 	24 	0.1
Restructuring 	56 	0.2 	61 	0.3
Earnings before provision for taxes on income 	6,662 	28.6 	3,940 	21.5 	69.1
Provision for taxes on income 	384 	1.7 	314 	1.7 	22.3
Net earnings 	6,278	$ 	26.9 	3,626	$ 	19.8 	73.1
Net earnings per share (Diluted) 	2.35	$ 	1.36	$ 	72.8
Average shares outstanding (Diluted) 	2,671.6 	2,665.5
Effective tax rate 	5.8 % 	8.0 %
Adjusted earnings before provision for taxes and net earnings (1)
Earnings before provision for taxes on income 	7,776	$ 	33.4 	5,337	$ 	29.1 	45.7
Net earnings 	6,625	$ 	28.4 	4,446	$ 	24.2 	49.0
Net earnings per share (Diluted) 	2.48	$ 	1.67	$ 	48.5
Effective tax rate 	14.8 % 	16.7 %
(1) See Reconciliation of Non-GAAP Financial Measures.
SECOND QUARTER
2021 	2020

-- 10 of 20 --

Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings
(Unaudited; in Millions Except Per Share Figures)
Percent
Percent 	Percent 	Increase
Amount 	to Sales 	Amount 	to Sales 	(Decrease)
Sales to customers 	45,633	$ 	100.0 	39,027	$ 	100.0 	16.9
Cost of products sold 	14,650 	32.1 	13,641 	35.0 	7.4
Gross Profit 	30,983 	67.9 	25,386 	65.0 	22.0
Selling, marketing and administrative expenses 	11,505 	25.2 	10,196 	26.1 	12.8
Research and development expense 	6,572 	14.4 	5,287 	13.5 	24.3
In-process research and development 	0 	0.0 	6 	0.0
Interest (income) expense, net 	76 	0.2 	(16) 	0.0
Other (income) expense, net 	(1,370) 	(3.0) 	(655) 	(1.7)
Restructuring 	109 	0.2 	119 	0.3
Earnings before provision for taxes on income 	14,091 	30.9 	10,449 	26.8 	34.9
Provision for taxes on income 	1,616 	3.6 	1,027 	2.7 	57.4
Net earnings 	12,475	$ 	27.3 	9,422	$ 	24.1 	32.4
Net earnings per share (Diluted) 	4.67	$ 	3.53	$ 	32.3
Average shares outstanding (Diluted) 	2,674.0 	2,671.0
Effective tax rate 	11.5 % 	9.8 %
Adjusted earnings before provision for taxes and net earnings (1)
Earnings before provision for taxes on income 	16,067	$ 	35.2 	12,581	$ 	32.2 	27.7
Net earnings 	13,549	$ 	29.7 	10,600	$ 	27.2 	27.8
Net earnings per share (Diluted) 	5.07	$ 	3.97	$ 	27.7
Effective tax rate 	15.7 % 	15.7 %
(1) See Reconciliation of Non-GAAP Financial Measures.
SIX MONTHS
2021 	2020

-- 11 of 20 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
(Dollars in Millions Except Per Share Data) 	2021 	2020 	2021 	2020
Net Earnings, after tax- as reported 	$6,278 	$3,626 	$12,475 	$9,422
Pre-tax Adjustments
Intangible Asset Amortization expense 	1,202 	1,127 	2,417 	2,245
Litigation related 	(23) 	613 	(23) 	733
IPR&D 	- 	6 	- 	6
Restructuring related 	108 	115 	212 	233
Acquisition, integration and divestiture related ¹ 	14 	29 	(524) 	(933)
Unrealized (gains)/losses on securities 	(243) 	(533) 	(208) 	(206)
Medical Device Regulation 	56 	37 	102 	51
Other 	- 	3 	- 	3
Tax Adjustments
Tax impact on special item adjustments 2 	(135) 	(253) 	(248) 	(520)
Tax legislation and other tax related 	(632) 	(324) 	(654) 	(434)
Adjusted Net Earnings, after tax 	$6,625 	$4,446 	$13,549 	$10,600
Average shares outstanding (Diluted) 	2,671.6 	2,665.5 	2,674.0 	2,671.0
Adjusted net earnings per share (Diluted) 	$2.48 	$1.67 	$5.07 	$3.97
Operational adjusted net earnings per share (Diluted) 	$2.42 	$4.91
Notes:
1
2 The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the
above pre-tax special items in arriving at adjusted earnings.
Second Quarter 	Six Months Ended
Acquisition, integration and divestiture related for the six months of 2021 primarily includes the gain on the divestiture
of two Pharmaceutical brands outside of the U.S. The six months of 2020 primarily includes a $983M Contingent
Consideration reversal related to the timing of certain developmental milestones associated with the Auris Health
acquisition.

-- 12 of 20 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Consumer Health 	Pharmaceutical 	Medical Devices 	Total
WW As Reported 	13.3% 	17.2% 	62.7% 	27.1%
U.S. 	12.4% 	12.2% 	77.2% 	24.9%
International 	14.1% 	23.7% 	51.6% 	29.5%
WW Currency 	4.1 	3.6 	5.5 	4.1
U.S. 	- 	- 	- 	-
International 	7.8 	8.3 	9.7 	8.6
WW Operational 	9.2% 	13.6% 	57.2% 	23.0%
U.S. 	12.4% 	12.2% 	77.2% 	24.9%
International 	6.3% 	15.4% 	41.9% 	20.9%
General Surgery
Advanced Sterilization Products 	1.2 	0.2
U.S. 	0.0 	0.0
International 	1.9 	0.4
All Other Acquisitions and Divestitures 	0.8 	0.6 	0.3 	0.6
U.S. 	0.6 	(0.1) 	0.7 	0.1
International 	1.1 	1.5 	0.0 	1.0
WW Adjusted Operational 	10.0% 	14.1% 	58.7% 	23.8%
U.S. 	13.0% 	12.1% 	77.9% 	25.1%
International 	7.4% 	16.8% 	43.8% 	22.4%
Adjusted Operational Sales Growth
SECOND QUARTER 2021 ACTUAL vs. 2020 ACTUAL
Segments
Note: Percentages are based on actual, non-rounded figures and may not sum

-- 13 of 20 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Consumer Health 	Pharmaceutical 	Medical Devices 	Total
WW As Reported 	5.2% 	13.3% 	32.7% 	16.9%
U.S. 	2.0% 	9.3% 	33.5% 	13.8%
International 	8.1% 	18.3% 	31.9% 	20.3%
WW Currency 	2.5 	3.0 	4.0 	3.2
U.S. 	- 	- 	- 	-
International 	4.8 	6.9 	7.4 	6.6
WW Operational 	2.7% 	10.3% 	28.7% 	13.7%
U.S. 	2.0% 	9.3% 	33.5% 	13.8%
International 	3.3% 	11.4% 	24.5% 	13.7%
General Surgery
Advanced Sterilization Products 	0.8 	0.2
U.S. 	0.0 	0.0
International 	1.5 	0.4
All Other Acquisitions and Divestitures 	0.6 	0.5 	0.2 	0.4
U.S. 	0.5 	(0.1) 	0.5 	0.1
International 	0.7 	1.2 	0.0 	0.8
WW Adjusted Operational 	3.3% 	10.7% 	29.7% 	14.4%
U.S. 	2.5% 	9.2% 	33.9% 	13.9%
International 	4.0% 	12.6% 	26.0% 	14.8%
Note: Percentages are based on actual, non-rounded figures and may not sum
Adjusted Operational Sales Growth
SIX MONTHS 2021 ACTUAL vs. 2020 ACTUAL
Segments

-- 14 of 20 --

REPORTED SALES vs. PRIOR PERIOD ($MM) 	REPORTED SALES vs. PRIOR PERIOD ($MM)
SECOND QUARTER 	SIX MONTHS
2021 	2020 	Reported 	Operational (1) Currency 	2021 	2020 	Reported 	Operational (1) Currency
CONSUMER HEALTH SEGMENT (2)
OTC
US 	675	$ 	627 	7.7% 	7.7% 	- 	1,274	$ 	1,316 	-3.2% 	-3.2% 	-
Intl 	633 	522 	21.2% 	10.4% 	10.8% 	1,208 	1,181 	2.3% 	-4.7% 	7.0%
WW 	1,307 	1,149 	13.8% 	8.9% 	4.9% 	2,482 	2,497 	-0.6% 	-3.9% 	3.3%
SKIN HEALTH / BEAUTY
US 	659 	536 	23.0% 	23.0% 	- 	1,293 	1,195 	8.2% 	8.2% 	-
Intl 	511 	471 	8.4% 	1.4% 	7.0% 	1,040 	929 	12.0% 	6.8% 	5.2%
WW 	1,170 	1,007 	16.2% 	12.9% 	3.3% 	2,333 	2,124 	9.8% 	7.6% 	2.2%
ORAL CARE
US 	165 	170 	-3.1% 	-3.1% 	- 	328 	346 	-5.2% 	-5.2% 	-
Intl 	260 	227 	14.6% 	6.7% 	7.9% 	514 	446 	15.3% 	10.2% 	5.1%
WW 	426 	397 	7.0% 	2.5% 	4.5% 	843 	792 	6.3% 	3.5% 	2.8%
BABY CARE
US 	97 	96 	0.8% 	0.8% 	- 	193 	188 	2.4% 	2.4% 	-
Intl 	290 	260 	11.5% 	6.6% 	4.9% 	583 	529 	10.2% 	9.0% 	1.2%
WW 	387 	356 	8.6% 	5.0% 	3.6% 	776 	717 	8.1% 	7.3% 	0.8%
WOMEN'S HEALTH
US 	3 	3 	-3.1% 	-3.1% 	- 	6 	7 	-16.0% 	-16.0% 	-
Intl 	227 	199 	14.2% 	9.2% 	5.0% 	446 	427 	4.5% 	3.1% 	1.4%
WW 	230 	202 	13.9% 	9.0% 	4.9% 	452 	434 	4.2% 	2.8% 	1.4%
WOUND CARE / OTHER
US 	153 	126 	20.9% 	20.9% 	- 	268 	245 	9.3% 	9.3% 	-
Intl 	64 	59 	7.3% 	-2.8% 	10.1% 	125 	111 	12.1% 	5.2% 	6.9%
WW 	216 	185 	16.6% 	13.4% 	3.2% 	393 	356 	10.2% 	8.0% 	2.2%
TOTAL CONSUMER HEALTH
US 	1,751 	1,557 	12.4% 	12.4% 	- 	3,362 	3,297 	2.0% 	2.0% 	-
Intl 	1,984 	1,739 	14.1% 	6.3% 	7.8% 	3,916 	3,624 	8.1% 	3.3% 	4.8%
WW 	3,735	$ 	3,296 	13.3% 	9.2% 	4.1% 	7,278	$ 	6,921 	5.2% 	2.7% 	2.5%
See footnotes at end of schedule
% Change 	% Change

-- 15 of 20 --

REPORTED SALES vs. PRIOR PERIOD ($MM) 	REPORTED SALES vs. PRIOR PERIOD ($MM)
SECOND QUARTER 	SIX MONTHS
PHARMACEUTICAL SEGMENT (2,3) 2021 	2020 	Reported 	Operational (1) Currency 	2021 	2020 	Reported 	Operational (1) Currency
IMMUNOLOGY
US 	2,748	$ 	2,362 	16.4% 	16.4% 	- 	5,161	$ 	4,772 	8.2% 	8.2% 	-
Intl 	1,483 	1,161 	27.7% 	18.2% 	9.5% 	2,984 	2,389 	24.9% 	17.0% 	7.9%
WW 	4,231 	3,523 	20.1% 	17.0% 	3.1% 	8,145 	7,161 	13.7% 	11.1% 	2.6%
REMICADE
US 	540 	593 	-9.1% 	-9.1% 	- 	1,029 	1,218 	-15.6% 	-15.6% 	-
US Exports (4) 93 	133 	-30.0% 	-30.0% 	- 	150 	243 	-38.2% 	-38.2% 	-
Intl 	255 	208 	22.4% 	11.1% 	11.3% 	487 	464 	4.9% 	-1.7% 	6.6%
WW 	888 	935 	-5.1% 	-7.6% 	2.5% 	1,665 	1,925 	-13.5% 	-15.1% 	1.6%
SIMPONI / SIMPONI ARIA
US 	290 	256 	12.8% 	12.8% 	- 	545 	528 	3.2% 	3.2% 	-
Intl 	294 	289 	1.7% 	-3.8% 	5.5% 	601 	547 	9.8% 	4.5% 	5.3%
WW 	584 	546 	6.9% 	4.0% 	2.9% 	1,146 	1,075 	6.6% 	3.8% 	2.8%
STELARA
US 	1,496 	1,138 	31.4% 	31.4% 	- 	2,827 	2,355 	20.0% 	20.0% 	-
Intl 	778 	558 	39.2% 	28.6% 	10.6% 	1,595 	1,161 	37.3% 	28.1% 	9.2%
WW 	2,274 	1,697 	34.0% 	30.5% 	3.5% 	4,422 	3,516 	25.8% 	22.7% 	3.1%
TREMFYA
US 	325 	241 	35.0% 	35.0% 	- 	599 	428 	40.0% 	40.0% 	-
Intl 	155 	101 	52.3% 	41.1% 	11.2% 	298 	210 	41.8% 	31.8% 	10.0%
WW 	479 	342 	40.2% 	36.8% 	3.4% 	897 	638 	40.6% 	37.3% 	3.3%
OTHER IMMUNOLOGY
US 	5 	- 	* 	* 	- 	12 	- 	* 	* 	-
Intl 	1 	3 	-61.3% 	-67.9% 	6.6% 	3 	6 	-51.2% 	-53.9% 	2.7%
WW 	7 	3 	* 	* 	* 	15 	6 	* 	* 	*
INFECTIOUS DISEASES
US 	444 	416 	6.8% 	6.8% 	- 	956 	852 	12.2% 	12.2% 	-
Intl 	585 	463 	26.3% 	18.2% 	8.1% 	1,079 	946 	14.1% 	7.8% 	6.3%
WW 	1,028 	878 	17.1% 	12.8% 	4.3% 	2,035 	1,798 	13.2% 	9.9% 	3.3%
COVID-19 VACCINE
US 	51 	- 	* 	* 	- 	151 	- 	* 	* 	-
Intl 	113 	- 	* 	* 	- 	113 	- 	* 	* 	-
WW 	164 	- 	* 	* 	- 	264 	- 	* 	* 	-
EDURANT / rilpivirine
US 	9 	10 	-9.3% 	-9.3% 	- 	19 	22 	-10.9% 	-10.9% 	-
Intl 	253 	246 	2.8% 	-4.0% 	6.8% 	486 	458 	6.0% 	-1.7% 	7.7%
WW 	262 	256 	2.3% 	-4.2% 	6.5% 	505 	480 	5.2% 	-2.1% 	7.3%
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
US 	368 	379 	-3.2% 	-3.2% 	- 	748 	775 	-3.5% 	-3.5% 	-
Intl 	137 	130 	5.5% 	-5.9% 	11.4% 	303 	314 	-3.5% 	-8.5% 	5.0%
WW 	505 	510 	-1.0% 	-3.9% 	2.9% 	1,051 	1,089 	-3.5% 	-5.0% 	1.5%
OTHER INFECTIOUS DISEASES
US 	16 	25 	-36.2% 	-36.2% 	- 	37 	54 	-31.3% 	-31.3% 	-
Intl 	81 	87 	-6.2% 	-13.4% 	7.2% 	177 	174 	1.8% 	-3.0% 	4.8%
WW 	98 	113 	-13.0% 	-18.5% 	5.5% 	215 	229 	-6.1% 	-9.7% 	3.6%
% Change 	% Change

-- 16 of 20 --

REPORTED SALES vs. PRIOR PERIOD ($MM) 	REPORTED SALES vs. PRIOR PERIOD ($MM)
SECOND QUARTER 	SIX MONTHS
2021 	2020 	Reported 	Operational (1) Currency 	2021 	2020 	Reported 	Operational (1) Currency
NEUROSCIENCE
US 	842 	778 	8.0% 	8.0% 	- 	1,613 	1,526 	5.6% 	5.6% 	-
Intl 	967 	809 	19.6% 	13.1% 	6.5% 	1,916 	1,719 	11.5% 	6.3% 	5.2%
WW 	1,808 	1,587 	13.9% 	10.6% 	3.3% 	3,529 	3,245 	8.7% 	6.0% 	2.7%
CONCERTA / Methylphenidate
US 	35 	55 	-36.0% 	-36.0% 	- 	82 	107 	-23.1% 	-23.1% 	-
Intl 	127 	94 	33.7% 	25.6% 	8.1% 	250 	212 	17.5% 	11.1% 	6.4%
WW 	161 	149 	8.1% 	3.0% 	5.1% 	332 	320 	3.9% 	-0.3% 	4.2%
INVEGA SUSTENNA / XEPLION /
INVEGA TRINZA / TREVICTA
US 	645 	576 	11.9% 	11.9% 	- 	1,234 	1,120 	10.2% 	10.2% 	-
Intl 	380 	303 	25.1% 	15.9% 	9.2% 	756 	642 	17.7% 	9.9% 	7.8%
WW 	1,024 	879 	16.4% 	13.3% 	3.1% 	1,989 	1,762 	12.9% 	10.1% 	2.8%
RISPERDAL CONSTA
US 	72 	74 	-3.0% 	-3.0% 	- 	139 	150 	-7.5% 	-7.5% 	-
Intl 	84 	79 	6.4% 	0.2% 	6.2% 	173 	173 	0.4% 	-4.6% 	5.0%
WW 	155 	153 	1.9% 	-1.3% 	3.2% 	312 	323 	-3.3% 	-6.0% 	2.7%
OTHER NEUROSCIENCE
US 	91 	75 	20.9% 	20.9% 	- 	158 	150 	5.6% 	5.6% 	-
Intl 	377 	331 	13.8% 	10.0% 	3.8% 	738 	691 	6.7% 	4.3% 	2.4%
WW 	468 	406 	15.1% 	12.0% 	3.1% 	896 	841 	6.5% 	4.5% 	2.0%
ONCOLOGY
US 	1,462 	1,181 	23.7% 	23.7% 	- 	2,839 	2,356 	20.5% 	20.5% 	-
Intl 	2,073 	1,609 	28.8% 	19.8% 	9.0% 	4,266 	3,448 	23.7% 	16.2% 	7.5%
WW 	3,535 	2,791 	26.7% 	21.5% 	5.2% 	7,105 	5,804 	22.4% 	17.9% 	4.5%
DARZALEX
US 	770 	492 	56.7% 	56.7% 	- 	1,461 	955 	53.1% 	53.1% 	-
Intl 	663 	409 	62.1% 	50.3% 	11.8% 	1,337 	883 	51.4% 	42.3% 	9.1%
WW 	1,433 	901 	59.2% 	53.8% 	5.4% 	2,798 	1,838 	52.2% 	47.9% 	4.3%
ERLEADA
US 	193 	136 	41.5% 	41.5% 	- 	364 	255 	42.7% 	42.7% 	-
Intl 	109 	33 	* 	* 	* 	199 	57 	* 	* 	*
WW 	302 	170 	77.6% 	73.7% 	3.9% 	563 	313 	80.0% 	76.4% 	3.6%
IMBRUVICA
US 	454 	447 	1.7% 	1.7% 	- 	898 	879 	2.2% 	2.2% 	-
Intl 	662 	502 	31.9% 	22.1% 	9.8% 	1,342 	1,101 	21.9% 	14.2% 	7.7%
WW 	1,116 	949 	17.7% 	12.5% 	5.2% 	2,241 	1,980 	13.2% 	8.9% 	4.3%
ZYTIGA / abiraterone acetate
US 	21 	87 	-75.3% 	-75.3% 	- 	71 	226 	-68.5% 	-68.5% 	-
Intl 	542 	480 	12.8% 	5.4% 	7.4% 	1,130 	1,032 	9.5% 	2.5% 	7.0%
WW 	563 	568 	-0.8% 	-7.1% 	6.3% 	1,201 	1,258 	-4.5% 	-10.3% 	5.8%
OTHER ONCOLOGY
US 	23 	20 	18.8% 	18.8% 	- 	44 	42 	6.3% 	6.3% 	-
Intl 	97 	185 	-47.2% 	-49.6% 	2.4% 	258 	375 	-31.0% 	-34.3% 	3.3%
WW 	120 	204 	-40.9% 	-43.0% 	2.1% 	302 	416 	-27.3% 	-30.2% 	2.9%
% Change 	% Change

-- 17 of 20 --

REPORTED SALES vs. PRIOR PERIOD ($MM) 	REPORTED SALES vs. PRIOR PERIOD ($MM)
SECOND QUARTER 	SIX MONTHS
2021 	2020 	Reported 	Operational (1) Currency 	2021 	2020 	Reported 	Operational (1) Currency
PULMONARY HYPERTENSION
US 	595 	545 	9.0% 	9.0% 	- 	1,168 	1,031 	13.2% 	13.2% 	-
Intl 	275 	243 	13.5% 	7.9% 	5.6% 	563 	503 	12.1% 	6.7% 	5.4%
WW 	870 	789 	10.4% 	8.7% 	1.7% 	1,731 	1,534 	12.9% 	11.1% 	1.8%
OPSUMIT
US 	290 	256 	13.6% 	13.6% 	- 	562 	485 	15.9% 	15.9% 	-
Intl 	172 	150 	14.9% 	9.0% 	5.9% 	351 	310 	13.1% 	7.6% 	5.5%
WW 	463 	406 	14.1% 	11.9% 	2.2% 	913 	795 	14.8% 	12.7% 	2.1%
UPTRAVI
US 	268 	254 	6.0% 	6.0% 	- 	527 	466 	13.3% 	13.3% 	-
Intl 	45 	28 	54.9% 	42.9% 	12.0% 	91 	66 	36.8% 	27.4% 	9.4%
WW 	313 	282 	11.0% 	9.8% 	1.2% 	618 	532 	16.2% 	15.0% 	1.2%
OTHER PULMONARY HYPERTENSION
US 	36 	37 	-2.4% 	-2.4% 	- 	78 	81 	-3.0% 	-3.0% 	-
Intl 	59 	64 	-8.2% 	-10.3% 	2.1% 	122 	126 	-3.5% 	-6.3% 	2.8%
WW 	95 	101 	-6.1% 	-7.5% 	1.4% 	200 	207 	-3.3% 	-5.0% 	1.7%
CARDIOVASCULAR / METABOLISM / OTHER
US 	780 	837 	-6.9% 	-6.9% 	- 	1,579 	1,643 	-3.9% 	-3.9% 	-
Intl 	346 	347 	-0.3% 	-8.4% 	8.1% 	674 	701 	-3.8% 	-9.9% 	6.1%
WW 	1,126 	1,184 	-5.0% 	-7.3% 	2.3% 	2,253 	2,344 	-3.9% 	-5.7% 	1.8%
XARELTO
US 	569 	559 	1.8% 	1.8% 	- 	1,158 	1,086 	6.6% 	6.6% 	-
Intl 	- 	- 	- 	- 	- 	- 	- 	- 	- 	-
WW 	569 	559 	1.8% 	1.8% 	- 	1,158 	1,086 	6.6% 	6.6% 	-
INVOKANA / INVOKAMET
US 	96 	132 	-27.0% 	-27.0% 	- 	183 	249 	-26.6% 	-26.6% 	-
Intl 	64 	47 	33.8% 	22.1% 	11.7% 	127 	105 	20.3% 	12.2% 	8.1%
WW 	160 	179 	-10.9% 	-14.0% 	3.1% 	310 	354 	-12.6% 	-15.0% 	2.4%
PROCRIT / EPREX
US 	59 	70 	-16.3% 	-16.3% 	- 	121 	146 	-17.3% 	-17.3% 	-
Intl 	69 	66 	3.7% 	-4.5% 	8.2% 	133 	145 	-8.2% 	-14.1% 	5.9%
WW 	127 	136 	-6.6% 	-10.6% 	4.0% 	254 	291 	-12.8% 	-15.7% 	2.9%
OTHER
US 	57 	78 	-26.7% 	-26.7% 	- 	117 	163 	-27.8% 	-27.8% 	-
Intl 	214 	234 	-8.4% 	-15.7% 	7.3% 	415 	451 	-8.1% 	-13.7% 	5.6%
WW 	271 	312 	-13.0% 	-18.4% 	5.4% 	532 	614 	-13.3% 	-17.4% 	4.1%
TOTAL PHARMACEUTICAL
US 	6,869 	6,120 	12.2% 	12.2% 	- 	13,315 	12,181 	9.3% 	9.3% 	-
Intl 	5,730 	4,632 	23.7% 	15.4% 	8.3% 	11,483 	9,705 	18.3% 	11.4% 	6.9%
WW 	12,599	$ 	10,752 	17.2% 	13.6% 	3.6% 	24,798	$ 	21,886 	13.3% 	10.3% 	3.0%
See footnotes at end of schedule
% Change 	% Change

-- 18 of 20 --

REPORTED SALES vs. PRIOR PERIOD ($MM) 	REPORTED SALES vs. PRIOR PERIOD ($MM)
SECOND QUARTER 	SIX MONTHS
MEDICAL DEVICES SEGMENT (2) 2021 	2020 	Reported 	Operational (1) Currency 	2021 	2020 	Reported 	Operational (1) Currency
INTERVENTIONAL SOLUTIONS
US 	475	$ 	255 	86.5% 	86.5% 	- 	909 	620 	46.7% 	46.7% 	-
Intl 	572 	335 	70.5% 	59.8% 	10.7% 	1,086 	697 	55.7% 	46.4% 	9.3%
WW 	1,046 	590 	77.4% 	71.3% 	6.1% 	1,995 	1,317 	51.5% 	46.5% 	5.0%
ORTHOPAEDICS
US 	1,323 	869 	52.3% 	52.3% 	- 	2,572 	2,119 	21.4% 	21.4% 	-
Intl 	904 	583 	55.1% 	43.2% 	11.9% 	1,768 	1,371 	29.0% 	20.2% 	8.8%
WW 	2,227 	1,451 	53.4% 	48.6% 	4.8% 	4,340 	3,489 	24.4% 	20.9% 	3.5%
HIPS
US 	234 	137 	70.5% 	70.5% 	- 	444 	343 	29.6% 	29.6% 	-
Intl 	159 	88 	78.6% 	64.3% 	14.3% 	305 	220 	38.3% 	28.6% 	9.7%
WW 	392 	226 	73.7% 	68.1% 	5.6% 	749 	563 	33.0% 	29.2% 	3.8%
KNEES
US 	210 	108 	94.3% 	94.3% 	- 	395 	322 	22.7% 	22.7% 	-
Intl 	140 	66 	* 	95.1% 	16.8% 	272 	196 	39.2% 	29.5% 	9.7%
WW 	350 	174 	* 	94.6% 	6.4% 	667 	517 	28.9% 	25.2% 	3.7%
TRAUMA
US 	447 	354 	26.0% 	26.0% 	- 	897 	761 	17.8% 	17.8% 	-
Intl 	263 	198 	32.7% 	22.7% 	10.0% 	545 	445 	22.5% 	14.4% 	8.1%
WW 	710 	553 	28.4% 	24.8% 	3.6% 	1,443 	1,207 	19.6% 	16.5% 	3.1%
SPINE, SPORTS & OTHER
US 	433 	270 	60.6% 	60.6% 	- 	836 	693 	20.7% 	20.7% 	-
Intl 	343 	230 	49.0% 	37.9% 	11.1% 	646 	510 	26.7% 	18.0% 	8.7%
WW 	776 	499 	55.3% 	50.2% 	5.1% 	1,482 	1,202 	23.2% 	19.6% 	3.6%
% Change 	% Change

-- 19 of 20 --

REPORTED SALES vs. PRIOR PERIOD ($MM) 	REPORTED SALES vs. PRIOR PERIOD ($MM)
SECOND QUARTER 	SIX MONTHS
2021 	2020 	Reported 	Operational (1) Currency 	2021 	2020 	Reported 	Operational (1) Currency
SURGERY
US 	1,035 	490 	* 	* 	- 	1,933 	1,334 	44.9% 	44.9% 	-
Intl 	1,487 	1,060 	40.2% 	30.6% 	9.6% 	2,961 	2,317 	27.8% 	20.4% 	7.4%
WW 	2,522 	1,551 	62.6% 	56.0% 	6.6% 	4,894 	3,651 	34.0% 	29.3% 	4.7%
ADVANCED
US 	459 	277 	65.4% 	65.4% 	- 	864 	658 	31.3% 	31.3% 	-
Intl 	708 	498 	42.2% 	32.5% 	9.7% 	1,421 	1,065 	33.4% 	25.6% 	7.8%
WW 	1,168 	775 	50.5% 	44.3% 	6.2% 	2,286 	1,723 	32.6% 	27.8% 	4.8%
GENERAL
US 	576 	213 	* 	* 	- 	1,069 	676 	58.1% 	58.1% 	-
Intl 	779 	562 	38.5% 	28.9% 	9.6% 	1,540 	1,252 	23.0% 	15.9% 	7.1%
WW 	1,354 	775 	74.7% 	67.8% 	6.9% 	2,608 	1,928 	35.3% 	30.7% 	4.6%
VISION
US 	467 	248 	88.3% 	88.3% 	- 	939 	687 	36.6% 	36.6% 	-
Intl 	716 	447 	60.0% 	53.7% 	6.3% 	1,389 	1,075 	29.2% 	24.6% 	4.6%
WW 	1,183 	695 	70.1% 	66.0% 	4.1% 	2,328 	1,762 	32.1% 	29.3% 	2.8%
CONTACT LENSES / OTHER
US 	352 	203 	73.3% 	73.3% 	- 	723 	549 	31.6% 	31.6% 	-
Intl 	517 	352 	47.0% 	41.9% 	5.1% 	1,003 	819 	22.5% 	18.5% 	4.0%
WW 	868 	554 	56.7% 	53.4% 	3.3% 	1,725 	1,368 	26.1% 	23.7% 	2.4%
SURGICAL
US 	115 	45 	* 	* 	- 	216 	138 	56.3% 	56.3% 	-
Intl 	199 	96 	* 	97.1% 	10.6% 	386 	256 	50.9% 	44.4% 	6.5%
WW 	314 	141 	* 	* 	* 	602 	394 	52.8% 	48.6% 	4.2%
TOTAL MEDICAL DEVICES
US 	3,299 	1,862 	77.2% 	77.2% 	- 	6,353 	4,760 	33.5% 	33.5% 	-
Intl 	3,679 	2,426 	51.6% 	41.9% 	9.7% 	7,204 	5,460 	31.9% 	24.5% 	7.4%
WW 	6,978	$ 	4,288 	62.7% 	57.2% 	5.5% 	13,557	$ 	10,220 	32.7% 	28.7% 	4.0%
* Percentage greater than 100% or not meaningful
(1) Operational growth excludes the effect of translational currency
(2) Unaudited
(3) Certain prior year amounts have been reclassified to conform to current year product disclosures
(4) Reported as U.S. sales
Note: Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and,
therefore, may not recalculate precisely.
% Change 	% Change

-- 20 of 20 --